Your shopping cart is currently empty

Niraparib, also know as MK-4827, is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. MK4827 inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $55 | In Stock | In Stock | |
| 10 mg | $79 | In Stock | In Stock | |
| 25 mg | $119 | In Stock | In Stock | |
| 50 mg | $147 | In Stock | In Stock | |
| 100 mg | $228 | In Stock | In Stock | |
| 200 mg | $343 | In Stock | In Stock | |
| 500 mg | $573 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $64 | In Stock | In Stock |
| Description | Niraparib, also know as MK-4827, is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. MK4827 inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway. |
| Targets&IC50 | PARP2:2.1 nM, tankyrase 1:570 nM, PARP1:3.8 nM, PARP4:330 nM, PARP3:1300 nM |
| Molecular Weight | 510.61 |
| Formula | C26H30N4O5S |
| Cas No. | 1613220-15-7 |
| Smiles | CC1=CC=C(S(=O)(O)=O)C=C1.O=C(N)C(C2=N3)=CC=CC2=CN3C(C=C4)=CC=C4[C@@H]5CCCNC5.O |
| Relative Density. | no data available |
| Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 1 mg/mL (1.96 mM), Sonication is recommended. DMSO: 247.5 mg/mL (484.71 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.92 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.